Clinical Trial Update: A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RO4929097 in patients with advanced renal cell carcinoma after VEGF/VEGFR therapy has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-10